Celldex Therapeutics, Inc. (CLDX) Q1 2013 Earnings Results

Celldex Therapeutics Misses on EPS — Stock Up 0.16%

Celldex Therapeutics reported a loss that was slightly larger than expected, which typically raises concerns among investors. However, the stock reacted positively, gaining 0.16%, likely due to management's focus on future projects and ongoing research efforts. This suggests that investors may still have confidence in the company's long-term potential despite the current losses.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.23	N/A	-7.98%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a cautious optimism about their ongoing projects. They acknowledged the challenges but emphasized their focus on future growth.

Management expressed a commitment to advancing their pipeline despite the loss.

They highlighted ongoing research efforts and potential future developments.

Celldex Therapeutics Misses on EPS — Stock Up 0.16%

Key numbers

Management commentary

Celldex Therapeutics, Inc.

More earnings this week

Celldex Therapeutics Misses on EPS — Stock Up 0.16%

Key numbers

Management commentary